Company

More than 247,000 customers from more than 20 countries have already provided for their family’s health with a cell depot at FamiCord AG. FamiCord AG continue to be one of Europe’s leading cell banks for umbilical cord blood. In Germany and the DACH region (DACH: Germany, Austria, Switzerland), FamiCord AG are the market leader by a clear margin.

FamiCord AG is the pioneer of stem cell banking in Europe. In the future, the Company is working on opening up new business areas in addition to its core business of umbilical cord blood banking and thus developing into the European market leader in cell banking. To achieve this strategic goal and the associated growth, the Management Board has identified the following four core areas:

New Research and Development Areas
Through targeted research and development of market oriented products and services, FamiCord AG continues to develop from a pure stem cell bank to a more broadly based cell bank that can supply the best available patient’s own cells for current and future cell therapies. FamiCord AG pursues a clearly focused innovation strategy by developing new products and services around the cryopreservation of stem cells from perinatal tissue or other suitable cell sources. To this end, the Company cooperates with selected renowned Research institutes and universities and, by storing different cell material, creates quality standards for later medical use. In this way, FamiCord AG opens up the potential to benefit from the increasing demand for cryopreserved cell material for personalized use in the field of regenerative medicine or cell therapies in the future. In addition, the value chain is to be expanded to include products and services for the pharmaceutical industry or governmental organizations. Currently, the cryopreservation of immune cells from peripheral blood is being prepared.

In all research & development activities, projects are selected on an economically reasonable scale, in line with market trends and with an adequate risk profile in the partnerships. In addition to the current core business, FamiCord AG continuously evaluates the need for new products for regenerative medicine (storage of adipose tissue as the starting point for mesenchymal stem cells and adipocytes) and for cell therapies (storage of T cells, natural killer (NK) cells, dendritic cells). The aim is to participate in the progress of further developments in the field of regenerative stem cell medicine and various immunoncological cell therapies in the medium and long term.

Expansion of the Core Business
FamiCord AG traditionally focuses on organic growth as part of its corporate strategy. In recent years, the company has successfully pushed ahead with internationalization, as the current storage of umbilical cord blood from more than 20 countries proves. The Company keeps on working on continuously increasing the market penetration in the highmargin core market DACH. At the same time, its market presence domestically and abroad is to be stabilized and expanded overall. For this purpose, FamiCord AG has a broad product portfolio in the field of storage of umbilical cord blood and umbilical cord tissue. The aim is to continuously expand the product range for stem cell deposits through active portfolio and life cycle management.

Inorganic Growth
A further focus of the growth strategy is on vertical and horizontal acquisitions in Europe, which should strategically strengthen the market position according to clearly defined parameters and open up additional synergies, particularly in the areas of marketing and sales as well as production and administration. The vertical portfolio expansion strategy involves opportunistic acquisitions along the value chain or of companies with complementary product offerings. The horizontal market expansion strategy focuses on the selective entry into specific European markets.

Ongoing Cost Efficiency
FamiCord AG continuously reviews all activities for their contribution to the current and future profitability of the Group. In order to secure future profitable growth on a sustainable basis, the Management Board will continue to examine further opportunities to increase cost efficiency.

The name FamiCord AG stands for compliance with the highest quality standards. FamiCord AG can only set and maintain these standards through consistent quality assurance. This is also reflected in the diverse permits and approvals, which secure the company’s innovation leadership among umbilical cord blood banks in Europe. For example, FamiCord AG is the only private stem cell bank in Germany that, in addition to a license for the storage of umbilical cord blood for autologous purposes, also possesses

Permits and approvals from the German Federal Institute for Vaccines and Biomedical Drugs (Paul Ehrlich Institute) for the distribution of umbilical cord blood preparations for therapeutic use in hematologic oncological diseases in siblings (familial-allogeneic application) and for third-party recipients (allogeneic application) permission to collect, process, cryopreserve and store umbilical cord tissue from Germany, Austria, Switzerland (DACH region) and Luxembourg

a patent from the European Patent Office (EPO) for a process for the disinfection, preparation, cryopreservation and cell isolation of umbilical cord tissue and the cells contained therein. Thus, FamiCord AG is currently the only German stem cell bank that is permitted to collect and store both blood and tissue from the umbilical cord of newborns in accordance with all applicable guidelines.

FamiCord AG has the necessary permits to offer customers the possibility of storing and dispensing for therapeutic purposes.